- Palatin Technologies | Home
At Palatin, we drive our culture with science Our employees have unparalleled expertise related to the melanocortin system allowing them to develop potent, selective treatments for patients with unmet medical needs
- Palatin Technologies | About Us
Robert has successfully managed several drug programs, including Palatin’s development of Vyleesi ® from phase 2 through NDA submission and FDA approval in 2019 as the only as-needed treatment for hypoactive sexual desire disorder (HSDD) Robert oversees all of Palatin’s drug development programs as well as leads clinical operations
- Palatin Technologies | Pipeline
Palatin is developing a truly novel class of drugs that selectively bind to melanocortin receptors (MCR), with both MCR1 and pan-agonists, to directly activate natural pathways that resolve disease inflammation in the eye
- Palatin Technologies | Investors
In this section, you will find information regarding the financial highlights of Palatin For your convenience, we provide a library of press releases, events, and webcasts, as well as prefiltered links to the Electronic Data Gathering, Analysis and Retrieval (EDGAR) database
- Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of . . .
CRANBURY, N J , April 10, 2025 PRNewswire — Palatin Technologies, Inc (the “Company”) (NYSE American:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced today that on April 10, 2024, NYSE American LLC (“NYSE American
- Palatin Appeals NYSE American Notice of Delisting
CRANBURY, N J , April 14, 2025 PRNewswire — Palatin Technologies, Inc (the “Company”) (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced today that it has formally appealed the NYSE Regulation determination to
- Palatin Technologies, Inc. NYSE American: PTN
Value of Palatin’s MC4R Agonist Portfolio New mechanisms will be required for obesity therapy and weight loss maintenance Obesity therapy will require combination therapy to achieve consistent, robust weight loss and for the long-term maintenance of healthy weight There are multiple high value intervention points for an MC4R agonist
- Palatin Provides Update on Anticipated 2025 Corporate Milestones
CRANBURY, N J , Jan 28, 2025 PRNewswire — Palatin Technologies, Inc (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system (MCRS), today provided an update on anticipated corporate milestones expected to occur in calendar year
|